Biotechnology Can Help Lessen The Effects Of Cow Farts – RedOrbit
By Dr. Matthew Watson
RedOrbit | Biotechnology Can Help Lessen The Effects Of Cow Farts RedOrbit The research team also tested a dairy biotechnology called rBST – a synthetic version of a cattle hormone that does not affect humans. Many dairy producers use rBST to help the cows produce more milk. The team injected one group of cattle with rBST and ... |
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) receives approval from … – NYSE Post
By Dr. Matthew Watson
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) receives approval from ... NYSE Post Boston, MA, 07/05/2013 (nysepost) - Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) recently announced that it obtained approval from the Austin Health Human Research Ethics Committee to commence an open label study for the company's drug on ... Prana Biotechnology, Ltd. ADR (NASDAQ:PRAN) prospects broaden after ...Avauncer Drug Manufacturers Other Stocks Buzz: Allergan, Inc.(NYSE:AGN), DURECT ...Techsonian Prana obtains HREC approval for open-label extension study in Alzheimer's ...Pharmaceutical Business Review |
Biotechnology market poised to reach $414.5B in 2017, says report – BioOptics World
By Dr. Matthew Watson
Biotechnology market poised to reach $414.5B in 2017, says report BioOptics World A new report from Transparency Market Research cites that the global biotechnology market was valued at $216.5 billion in 2011, and expects that it will reach $414.5 billion in 2017. Covering several market segments—including polymerase chain reaction ... |
Music to your ears? Try a headphones implant like Rich Lee
By Dr. Matthew Watson
'Grinder' can listen to music player by wearing a loose wire coil around his neckDon't offer Rich Lee a pair of headphones to listen to music: he's already got a pair, even though you can't see them. They're implanted in his ears – a procedure carried out by a "body modification" expert.Now, by connecting his music player to a loose wire coil around his neck (which he can tuck under his shirt), Lee can listen to music without blocking out the outside world. The tiny magnets implanted invisibly in his outer ears pick up the signal and generate sound.But that's only the beginning. Lee, 34, who works as a salesman, intends to hook it up to an ultrasonic rangefinder – effectively giving himself bat-like echolocation. And he would like to have X-ray vision, super-strength, and anything else...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
California Legislation, Human Egg Sales and Profits
By Dr. Matthew Watson
California legislation to allow women
to be paid for their eggs for scientific research is sailing toward
final passage literally swaddled in motherhood and apple pie
arguments. Missing from the debate is a key reason behind
the bill – building profits for what some call the “baby
business.”
The legislation is touted as providing
equal treatment for women, permitting them to be paid for supplying
eggs for stem cell and other research, much as men are paid for
sperm. It also would put women who sell their eggs for research on an
equal economic footing with women who sell their eggs for fertility
treatments, which is currently permitted under state law. Payments to
those women range from an average of $9,000 to as much as $50,000,
according to a legislative analysis of the bill.
Assemblywoman Susan Bonillla,
D-Concord, author of the bill(AB926), says,
“It is time to let women, just as any
other research subject, make an informed decision as to
participation, and justly compensate them for doing so.”
has had serious impact on fertility research. In a legislative bill analysis, she says,
“It has led to a de facto prohibition
on women’s reproductive research in California, adversely
impacting the same women that the ban intended to protect. With few
oocytes donated, fertility research and fertility preservation
research has been at a standstill. This greatly affects women
suffering from fertility issues and women facing cancer who would
like to preserve their oocytes.”
behalf of an industry group, the American Society for Reproductive Medicine of Alabama. The fertility or baby business, which is largely
unregulated, brings in about $5 billion annually in the United
States from something like 500 clinics. It has grown rapidly over the
last couple of decades, but is likely heading for a soft spot.
on the Internet discussing the industry's economic challenges.
However, demographic studies show that the size of the key market
for fertility services is stagnating. A 2012 report by the federal
government projects that the number of women in the 35 to 44 age
group, prime consumers of fertility services, is likely to grow only
0.5 percent from 2010 to 2020. And since that forecast was made, the
Census Bureau has downgraded its projections for total population
growth.
a new, potential revenue stream for the industry. Fertility clinics
would be able to buy the eggs and then resell them to researchers,
adding premiums for eggs from women with special characteristics. The bill would also add a tool for bringing down the cost of fertility
treatments, which can run as much as $12,000 to $17,000 a round or
more and require several rounds, according to the NIH. Clinics could discount those prices for some women, bringing in
new customers, if they agree to authorize the use of excess eggs for
scientific research.
pernicious. What is pernicious is the absence of discussion of the
economics of the legislation. Without a full understanding of all
that is at stake, including economic issues and motivations,
legislators, the governor and the public are hard-pressed to make
good decisions about a significant change in California law.
raised serious questions about the treatment of women by fertility
clinics, noting that the bill would turn egg providers into “vendors”
– not patients of the clinics. The Center for Genetics and Society
in Berkeley has captured the arguments in opposition including
testimony before a Senate committee hearing early in June.
lost a 31-year-old daughter to cancer seven years after the younger
woman sold her eggs three times, told lawmakers,
“Unlike infertile women who are
considered patients, egg donors are treated as vendors( (her italics).
When they walk out of the IVF clinic, no one keeps track of them.
My daughter’s death was not reported. The long-term risks of egg
donation are unknown."
now a physician with a Ph.D. in biology, testified that she wound up
in an intensive care unit after 60 eggs were extracted from her in
2001. She said,
“I fear that cases like mine are
buried deep by fertility centers concerned about their image. An
industry thriving on profits and reputation has little incentive to
report adverse events, or protect the health and medical rights of
donors.”
cell agency on all this? The agency has not taken a position on the
bill nor have any major research organizations. The measure does not
change the law affecting agency-funded research, which bans the use of
compensation for eggs in its research. Enactment of the law, however, would
create a two-tier stem cell research standard in California, one for
scientists not constrained by the payment ban and another for those
who could use the full range of research tools. Some stem cell
researchers may well think that they have become disadvantaged as a
result.
(Editor's note: An earlier version of this article said the IVF business generated $4 billion in revenues annually. More recent estimates place it at $5 billion.)
Challenge to WARF hESC Patents Cites Recent U.S. Supreme Court Decision
By Dr. Matthew Watson
are being challenged in a new legal filing that cites the recent U.S.
Supreme Court decision that barred the patenting of human genes.
Wisconsin Alumni Research Foundation (WARF), which holds the patents on the
much-heralded work performed by Jamie Thomson at the University of Wisconsin. The lawsuit was filed
by the Public Patent Foundation of New York City on behalf of
Consumer Watchdog, a nonprofit group in Santa Monica, Ca. Jeanne
Loring, director of the Center for Regenerative Medicine at the
Scripps Research Institute, is also involved along with Alan
Trounson, president of the California stem cell agency. The agency
itself is not a party.
so-called Myriad decision last month by the nation's highest court which said,
“Myriad did not create anything. To
be sure, it found an important and useful gene, but separating that
gene from its surrounding genetic material is not an act of
invention.”
"WARF did not create or alter the
properties inherent in stem cells any more than Myriad created or
altered the genetic information encoded in the DNA it claimed.”
an earlier decision by the U.S. Patent Office. The Public Patent
Foundation, which was a successful party in the Myriad case, did the earlier legal work on the challenge to the WARF patents as well as this
week's appeal.
said the WARF patents have "put a severe burden on taxpayer-funded
research in California.”
“We don't want to do anything that
gets in the way of finding treatments for some of the biggest killers
today, so we feel that all patients with all kinds of diseases
deserve to have access to these kinds of cells.”
"Human embryonic stem cells hold
great promise for advancing human health, and no one has the ethical
right to own them.”
said,
“The best course if WARF truly
cares about scientific advancement would be to
simply abandon these over-reaching patent claims.”
Diego U-T cited intellectual property attorney Lisa Haile of DLA
Piper as saying,
“A successful use of the Myriad case
as a precedent for throwing out the foundation’s patent would open
the door to similar challenges in just about any biotech product
using material derived from life.”
WARF made no immediate comment.
appeared in the Milwaukee Journal, Genomeweb and the LaCross Tribune.
Stem Cell Therapy and Regenexx KUSA TV News – Video
By Dr. Matthew Watson
Stem Cell Therapy and Regenexx KUSA TV News
By: Regenexx
Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India. – Video
By Dr. Matthew Watson
Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India.
Improvement seen after Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. His neck and...
By: neurogenbsi
Read more from the original source:
Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India. - Video
Giving hope: The promise of stem cell therapy – Video
By Dr. Matthew Watson
Giving hope: The promise of stem cell therapy
MANILA - As stem cell treatment begins to gain traction among Filipinos, a surgeon believes the country is now entering a new phase in medicine.
By: TheABSCBNNews
Read more:
Giving hope: The promise of stem cell therapy - Video
Old wheat, new genetic engineering may protect crop from deadly pest – Ars Technica
By Dr. Matthew Watson
Ars Technica | Old wheat, new genetic engineering may protect crop from deadly pest Ars Technica Currently, roughly 20 percent of humanity's caloric intake comes from wheat. Agricultural strains, specialized for bread or pasta production, have been bred for high productivity and resistance to many agricultural pests. But over the past few years ... Genes Found to Fight Wheat DiseasePayvand |
Puma Biotechnology to Join Russell 3000 Index – EON: Enhanced Online News (press release)
By Dr. Matthew Watson
Puma Biotechnology to Join Russell 3000 Index EON: Enhanced Online News (press release) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, is set to join the broad-market Russell 3000® Index following Russell Investments' annual reconstitution of its comprehensive set ... |
Prosensa Holding (RNA) IPO Opens Sharply Higher – StreetInsider.com (subscription)
By Dr. Matthew Watson
Prosensa Holding (RNA) IPO Opens Sharply Higher StreetInsider.com (subscription) Prosensa Holding is an innovative biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company's primary focus is on rare ... Prosensa leaps in 1st day of Nasdaq tradingThe Idaho Statesman |
A joint campaign against GM crops, Biotechnology Bill – The Hindu
By Dr. Matthew Watson
The Hindu | A joint campaign against GM crops, Biotechnology Bill The Hindu Cutting across party lines, several political leaders participated on Tuesday in a joint campaign with civil society groups and farmers' organisations against Genetically Modified crops and the Biotechnology Regulatory Authority of India (BRAI) Bill at ... |
Biotechnology Recognized for contribution to renewable energy. – ThomasNet Industrial News Room (press release)
By Dr. Matthew Watson
Biotechnology Recognized for contribution to renewable energy. ThomasNet Industrial News Room (press release) June 28, 2013 - BIO applauded President Barack Obama's recognition of contributions made by biotechnology to design of new biofuels and to agricultural productivity in the President's Climate Action Plan. BIO President and CEO Jim Greenwood ... BIO Applauds Legislation That Levels the Playing Field for Renewable ChemicalsThe Herald | HeraldOnline.com |
Annual Shareholders’ Meeting of Cytos Biotechnology Ltd: Shareholders … – PR Newswire (press release)
By Dr. Matthew Watson
Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders ... PR Newswire (press release) Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders' Meeting 2013. The Annual Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in ... |
What Is Biotechnology Again? – Motley Fool
By Dr. Matthew Watson
What Is Biotechnology Again? Motley Fool Understanding the ins and outs will come with time, but to get there investors need to grasp some of the basics. For instance: the difference between biotechnology and "traditional" pharmaceuticals. The two terms are often used (mistakenly ... |
Angelina Jolie, Medical College of Wisconsin and genome sequencing – The Business Journal of Milwaukee (blog)
By Dr. Matthew Watson
Angelina Jolie, Medical College of Wisconsin and genome sequencing The Business Journal of Milwaukee (blog) Howard Jacob, director of the college's Human and Molecular Genetics Center, told me. “That's really where we want to spend our time. There are plenty of places out there that have more firepower in the research arena than we do.” Rich Kirchen is The ... |
Targeted viral therapy destroys breast cancer stem cells in preclinical … – EurekAlert (press release)
By Dr. Matthew Watson
Targeted viral therapy destroys breast cancer stem cells in preclinical ... EurekAlert (press release) ... Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. |
OICR congratulates Dr. Thomas J. Hudson on being named to the Order of … – Canada NewsWire (press release)
By Dr. Matthew Watson
OICR congratulates Dr. Thomas J. Hudson on being named to the Order of ... Canada NewsWire (press release) In 2007, Dr. Hudson was appointed Professor in the Departments of Molecular Genetics and Medical Biophysics at the University of Toronto and he is a fellow of the Royal Society of Canada. He is editor-in-chief of the journal Human Genetics and has ... |
Student news published June 28, 2013 – Helena Independent Record
By Dr. Matthew Watson
Student news published June 28, 2013 Helena Independent Record A 2010 graduate in cell biology, Harlen will use his fellowship to research molecular genetics in the department of genetics at Harvard Medical School. He would eventually like to become a professor. MedStart Summer Camp attendees. Kaitlin Kroll and ... |